Drug–Drug Interactions—New Approaches and Perspectives
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".
Deadline for manuscript submissions: 10 August 2024 | Viewed by 4265
Special Issue Editor
Interests: drug repositioning; network pharmacology; drug–drug interactions; drug–drug similarity networks; drug solubility; drug bioavailability; biopharmacy; drug–cyclodextrin inclusion complexes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Drug–drug interactions represent a crucial factor affecting pharmacotherapeutic success. Good knowledge of the mechanisms of drug–drug interactions is vital for avoiding them. Accordingly, pharmacists and prescribing doctors must consider the clinical context when assessing drug interactions; the clinical relevance of the same drug combination can differ in distinct pathophysiological states (e.g., extreme ages, pregnancy, diabetes, immune-system-related disorders, and so on). Multiple morbidities in the elderly or specific clinical circumstances that require more than two drugs are conditions for drug–drug interactions that could affect the therapeutic outcome. To evaluate drug–drug interaction in a clinical context, healthcare specialists can use multiple online tools to check drug interactions. However, in practice, they may obtain contradicting results for the same drug combination (An even more unwanted case is when an online drug–drug interaction checker does not include a required drug).
Extensive wet-lab experiments to screen all potential drug–drug interactions will address the information uncertainty in many online check tools (based on existing drug–drug interaction databases). Unfortunately, such an approach would be unfeasible, as covering the entailed search space requires enormous resources. This situation calls for computational methods to predict drug–drug interactions; such tools would substantially narrow the wet-lab experiments search space.
This Special Issue calls for papers presenting multiple aspects of drug interactions relevant to their assessment: mechanisms, evaluation of the clinical relevance, prediction algorithms, electronic alert systems, and the Internet of Medical Things (IoMT) applied in the clinical evaluation of drug–drug and drug–disease interactions.
Dr. Lucreția Udrescu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
